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Debata I: LEFT MAIN stenosis
PCI v.s. CABG – surgical side 
Special hospital for surgery 




Which procedure is the best?
Growing uncertainty over role and value of PCI in Multivessel
and/or Left Main
Outcomes (↑ mortality, ↑ reintervention, ↑ risks with DES) •
Are patients adequately informed of the risks and limitations 
of PCI to allow informed consent?
Fergusson Lecture at STS 2006 ATS 2006; 82: 1966-76 •www.sts.org
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• Aim today is to update that lecture and focus on the key issues
• 1. Evidence basis for LEFT MAIN stenosis- PCI v.s. CABG 
• 2. Evidence basis (absence of ?) for PCI with and without stents
• 3. Cost effectiveness of CABG vs PCI
• 4. Appropriateness of cardiology guidelines for PCI ?
• 5. What information is given to patients and by whom
Fergusson Lecture at STS 2006 ATS 
2006; 82: 1966-76 •www.sts.org
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WHY DOES CABG HAVE SUCH A SURVIVAL BENEFIT OVER PCI ?
• CABG TREATS BOTH THE „CULPRIT CULPRIT‟LESION AND FUTURE 
CULPRIT LESION(S), OF ANY COMPLEXITY •
• Patients with CAD have diffusely unstable coronary endothelium
• CABG places grafts to mid vessel thereby protecting whole zones of vulnerable 
proximal myocardium against culprit and „de novo‟ lesions
• PCI only deals with „suitable‟ localised proximal culprit lesions and has no 
prophylactic benefit against new disease
• PCI is unlikely to ever match the results of CABG for LM/MVD
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“There is no survival difference between CABG and PCI”
The most widely perpetuated myth in cardiovascular medicine 
“The great enemy of the truth is very often not the lie –
deliberate, contrived and dishonest –but the myth –
persistent, persuasive and unrealistic.”John F Kennedy.
Based on 15 RCT where results were stacked against CABG 
Ignoring consistently strong data from numerous large 
databases which demonstrate survival benefit of CABG
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What is the Scale of the Problem with Stent Thrombosis in Over Six million 
Implanted Drug Eluting Stents?
Universally agreed there is a problem but scale uncertain because of   
limited duration and completeness of follow-up 
FDA (Dec 2006) accept ↑ risk of thrombosis with „off-label‟ use
Thrombosis can occur even on two antiplatelets but highest risk if 
•one or both antiplatelets stopped 
•„Off Label‟ Lesions (long/multiple/overlapping/ bifurcation)=80% 
Patients (elderly, diabetes, ACS, low EF, renal failure)
AHA/ACC recommend aspirin + clopidogrel for > one year (JACC 2007)  
Bleeding risks 
Cost of clopidogrel ($ 1400/year)
„Debating the risks of drug eluting stents‟ Shuchman NEJM 24 Jan 2007
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Summary for CABG vs PCI in stable multivessel CAD
• For CABG there is consistently strong evidence from databases of >80,000 patients of a significant 
survival benefit and a marked decrease in the need for reintervention
• FOR PCI 
• There is no evidence from RCT to support its use in multivessel disease (as these patients were excluded 
from RCT) 
• All available evidence from large databases show that PCI impairs survival vs CABG and ↑ 
reintervention by X7 
• Meta-analyses of PCI vs medical therapy show 
• No improvement in survival 
• No reduction in myocardial infarction 
• No reduction in repeat intervention (? ↑) 
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ACC/AHA Guidelines for ACBP 2004
Class I:
-LMN 50%
-LMN equivalent with 70% LAD and LCx proximal stenosis
-Multivessel dissease low ejection fraction
-Proximal LAD stenosis with low ejection fraction
Cost-benefit from stenting
1. Myocardial infarction?
2. Unstabile coronary syndrom
3. Shock cardiogenes




Why is PCI replacing CABG against all the available evidence?
• Califf RM. Stenting or Surgery JACC 2005; 46: 589 589-91 :
• “It is likely that most people undergoing coronary angiography are not told the 
entire story when a decision is made about undergoing PCI … self-referral.. 
financial incentives ..without surgical opinion the patient is in no position to have 
rational input into the decision”
Decision depends from patients 
information 
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“patients do not want operations”
- No one wants any operation
- Patient’s decision on CABG depends who presents 
information and its balanceno patient wants ‘cracking the 
chest’ if the same effect can be achieved with PCI
- But most patients want the best treatment and many will 
accept an operation if it increases survival by 5% (or 
reduces risk of mortality by 1/3) within 3-5 years
and allows them to get on with life without repeat interventions 






Do you agree with the authors of the SYNTAX trial 
that CABG should be the standard of care?
•Yes 57%
•No 43%
Will the SYNTAX results change the advice you give
your patients about the choice of treatments?
•Yes 54%
•No 46%
Poll Closed Mar. 4, 2009
( total responses 28 543 )
What every surgeon should be able to tell their cardiologists about 

























• - CABG with EKC
• - CABG with EKC without cardioplegy
• - CABG in off-pump conditions
• - CABG for ischemic heart failure
Type of grafts
• LIMA; RIMA
• Vena saphena magna
• Radial artery
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Aorto-coronary by-pass n = 5142 pts
CABG + IABP pre -op. 252pts
CABG + IABP intra-op. 82pts
CABG + IABP post-op. 45pts
CABG 5142 62,5%
OPCAB 745 14,5%
Total arerial revasc. 2894 56.3%
CABG+aneurysmetoy 740 14.4%
CABG + valv surgery 763 15.3%
120 pts with haemodynamis instability- acute 
coronary syndrom
Mortality rate 1,2%    - 61 pts.
Follow – up > 10 y.
-
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Surgery  for patients with terminal ishemic heart-
ventriculoplasty &by-pass surgery N-740 (14,4%)
Direct circular repair for anterior left ventricle aneurysm N=433pts
Haemodinamic parameters:
EDV=345  33.4ml      EF=27  6.2%
ESV= 259  26.5ml    Mortality rate -5,6 (21 pts)
Surgery- ventriculoplasty with posterior cuneate or separate 
posterior linear reconstruction  N=96 pts
Haemodinamic parameters:
EDV=367  23.5ml      EF=25  5.6%
ESV= 299  22.4ml  Mortality rate  4 (5,6) % pts
Transventricular mitral valve reconstruction for pts with LV
aneurysm and mitral valve insuff N=56pts
EDV=367  23.5ml      EF=25  5.6%
ESV= 299  22.4ml  Mortality rate 4 (8,6 %) pts
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Surgery for patients in cardiogenic shock and   
postinfarction VSD         
Haemodinamic stabilisation
Pre-operative IABP 5 
Cathecholemines if necessery
Postinfarction VSD - 5 (6%) 




EDV=232  30.4ml      EF=25  4.2%
ESV= 189  28.5ml
Early mortality rate 0
Late mortality rate 1 pts
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Surgery – OPCAB left ventricle plication (n=37pts) 
52  6.4y  Sex f/m  20/17
Heamodinamic instability 2 (6%) pts
Pre-operative IABP 4(12%) pts
Post-operative IABP 0
Haemodinamic parameters:
EDV=250  13.7ml      EF=30  4.8%
ESV= 169  19.4ml
Prezented on X Jubillee congress 
CTT/ Mayami 03/2004 year
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Coronary Artery Bypass Grafting in Awake 
Settings
Awarded on the 6th annual meeting of ISMICS in San 
Francisco (06/2003) as the best oral abstract and the 

































Complications rate N= 5142
Early survival (30 days)   98.8%
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Mortality rate                             N = 8217
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